177Lutetium-PSMA-617 治疗转移性去势抵抗性前列腺癌的全身治疗更新:ASCO 指南快速推荐更新。
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
发表日期:2023 Nov 06
作者:
Rohan Garje, R Bryan Rumble, Rahul A Parikh,
来源:
Best Pract Res Cl Ob
摘要:
ASCO 快速建议更新强调了对选择 ASCO 指南建议的修订,以响应新的和改变实践的数据的出现。快速更新得到证据审查的支持,并遵循 ASCO 指南方法手册中概述的指南制定流程。这些文章的目的是及时传播最新的建议,以便更好地向健康从业者和公众通报最佳的癌症护理选择。指南和更新无意取代治疗提供者的独立专业判断,也不考虑患者之间的个体差异。请参阅附录了解免责声明和其他重要信息(附录 1 和附录 2,仅在线)。
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).